钙激活钾通道蛋白4在甲状腺乳头状癌组织的表达及临床意义  

Expression and clinical significance of potassium calcium-activated channel subfamily N member 4 in papillary thyroid carcinoma

作　　者：姜斌 李汉宁 逯超 Jiang Bin;Li Hanning;Lu Chao(Department of Thyroid and Breast Surgery,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China)

机构地区：[1]华中科技大学同济医学院附属同济医院甲状腺乳腺外科,武汉430030

出　　处：《中华实验外科杂志》2024年第6期1261-1264,共4页Chinese Journal of Experimental Surgery

摘　　要：目的探讨钙激活钾通道蛋白4(KCNN4)在甲状腺乳头状癌(PTC)中的表达情况、其与患者临床病例特征及预后的关系。方法收集2021年1月至2021年6月在华中科技大学同济医学院附属同济医院甲状腺乳腺外科手术切除的PTC及癌旁甲状腺组织共116例,通过免疫组织化学实验检测KCNN4的表达水平,并分析不同KCNN4表达水平的患者之间的临床病例特征及预后的差异;通过细胞计数试剂盒(CCK-8)实验和划痕愈合实验检测KCNN4对PTC细胞增殖和迁移能力的影响。组间比较采用非配对t检验;KCNN4与患者临床病理特征的关系采用χ^(2)检验或Fisher精确检验,生存分析采用Kalpan-Meier法。结果KCNN4在PTC中的表达显著高于癌旁组织(免疫组织化学评分:8.17±2.46比3.26±0.72,t=8.44,P<0.05);KCNN4的表达与肿瘤多灶性情况[低表达比高表达(下同),单灶为31比50,多灶为6比29,χ^(2)=2.24,P<0.05]、肿瘤TNM分期(Ⅰ~Ⅱ期为35比60,Ⅲ~Ⅳ期为2比19,χ^(2)=2.43,P<0.05)及甲状腺外侵犯显著相关(无腺外侵犯为34比59,有腺外侵犯为3比20,χ^(2)=2.17,P<0.05),而与患者年龄(≤55岁为12比28,>55岁为25比51,χ^(2)=0.32,P>0.05)、性别(男为5比16,女为32比63,χ^(2)=0.88,P>0.05)、是否合并有桥本甲状腺炎无关(无桥本甲状腺为23比56,有桥本甲状腺炎为14比23,χ^(2)=0.94,P>0.05)。KCNN4高表达患者的无复发生存率低于低表达组患者(复发率:8.86%比0%,HR=2.42,P<0.05);CCK-8实验表明,敲减KCNN4后的KTC-1和BCPAP细胞的增殖能力低于对照组细胞[KTC-1对照组比短发卡RNA(shRNA)转染组,72 h:1.28±0.11比0.47±0.06,t=8.28,P<0.05;96 h:1.82±0.24比0.61±0.10,t=10.45,P<0.05;BCPAP对照组比shRNA转染组,72 h:1.37±0.19比0.51±0.07,t=6.14,P<0.05;96 h:2.03±0.47比0.84±0.20,t=3.99,P<0.05]。划痕愈合实验显示,敲降KCNN4后的KTC-1和BCPAP细胞划痕愈合能力低于对照组细胞[KTC-1对照组比shRNA转染组24 h划痕愈合百分比:(66.47±7.60)%比(33.41±3.76)%,t=6.28,P<Objective To investigate the expression of potassium calcium-activated channel subfamily N member 4(KCNN4)in papillary thyroid carcinoma(PTC)and its association with clinical characteristics and prognosis.Methods Immunohistochemistry was performed to determine the expression level of KCNN64 in 116 cases of PTC and adjacent normal thyroid tissues collected from the Department of Thyroid and Breast Surgery,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology from January 2021 to June 2021.The clinical characteristics and prognosis were analyzed among patients with different levels of KCNN4 expression.Additionally,the impact of KCNN4 on PTC cell proliferation and migration was assessed using CCK-8 assay and wound healing assay.Unpaired t test was used for comparison between groups.The relationship between KCNN4 and clinicopathological characteristics of patients was analyzed byχ^(2)test or Fisher exact test.Survival analysis was performed by Kalpan-Meier method.Results The expression of KCNN4 in PTC was significantly higher than that in adjacent tissues(immunohistochemical score:8.17±2.46 vs.3.26±0.72,t=8.44,P<0.05).The expression of KCNN4 was significantly correlated with tumor multifocality[low expression group vs.high expression group(the same below),31 vs.50 in single lesion,6 vs.29 in multiple lesions,χ^(2)=2.24,P<0.05],tumor TNM stage(Ⅰ-Ⅱstage:35 vs.60,Ⅲ-Ⅳstage:2 vs.19,χ^(2)=2.43,P<0.05)and extrathyroidal extension(without extrathyroidal extension:34 vs.59,with extrathyroidal extension:3 vs.20,χ^(2)=2.17,P<0.05),while irrelevantly correlated with age(≤55 years old:12 vs.28,>55 years old:25 vs.51,χ^(2)=0.32,P>0.05),gender(male:5 vs.16,female:32 vs.63,χ^(2)=0.88,P>0.05)and Hashimoto’s thyroiditis(without Hashimoto’s thyroiditis:23 vs.56,with Hashimoto’s thyroiditis:χ^(2)=0.94,P>0.05).The recurrence-free survival rate of patients with high KCNN4 expression was lower than that of patients with low KCNN4 expression(recurrence rate:8.86%vs.0%,HR=2.42,P<0.05).C

关 键 词：钙激活钾通道蛋白4 甲状腺乳头状癌 临床病例特征 预后 

分 类 号：R736.1[医药卫生—肿瘤]